Crystal structures of human TIM members: Ebolavirus entry-enhancing receptors

December 15, 2015

Since first identified in 1976, Ebola virus has caused a total of 24 outbreaks involving 1,716 cases according to the World Health Organization (WHO) statistics. The current outbreak in West Africa, with the first case notified in March 2014, is the largest and most complex Ebola outbreak and has more than 28,000 infection cases and over 11,000 deaths as of December 2015. The WHO's emergency committee unanimously agreed that the current outbreak--centered in Guinea, Liberia, and Sierra Leone--was "an extraordinary event and a public health risk to other states", and declared the outbreak a "public health emergency of international concern".

Ebola virus is a group of enveloped viruses that can infect both primates and humans. They are taxonomically categorized into five species, including Zaire (ZEBOV), Sudan (SUDV), Tai Forest (TAFV), Bundibugyo (BDBV) and Reston (RESTV) ebolavirus. The severely high mortality rate related to Ebola virus infection (25% to 90% in past outbreaks) has made the virus one of the most deadly pathogens. Over the past few decades, scientists paid great efforts to have a deeper understanding of this most virulent pathogen and revealed a series of receptors which play important roles in cell entry of Ebola virus.

Human T-cell immunoglobulin and mucin domain (hTIM) receptor was recently identified as the entry-enhancing receptor for various enveloped viruses, including Ebola virus. This hTIM-mediated entry is highly dependent on the immunoglobulin variable (IgV)-like domain of the receptor which specifically recognizes envelope phosphotidylserine (PS). Of the three hTIMs (hTIM-1, -3, and -4), however, neither their IgV domain structures nor the PS-binding basis is available thus far, though their murine homologues have been structurally well-defined. More than that, functional details of how the hTIMs work in the processing of cell entry of Ebola virus are not well known.

In an article entitled "Crystal structures of human TIM members: Ebolavirus entry-enhancing receptors", researchers, led by Prof. George Fu Gao, from Chinese Academy of Sciences and Sichuan University showed that lentivirions pseudotyped with either the 1976-ZEBOV or the 2014(C05)-ZEBOV glycoproteins (GPs) exhibit similarly-enhanced cell entry via hTIM-1, though the two GPs contain multiple residue variance. As expected, this hTIM-mediated enhancement of Ebola virus infection is highly dependent on the PS-binding capacity of the receptor. Furthermore, hTIM-4 with a mucin domain comparable to that of hTIM-1 in length, but not hTIM-3 that contains only limited numbers of mucin repeats, efficiently enhance pseudovirus infection, demonstrating, as previously reported, an important role of the hTIM mucin domain in facilitating the virus entry. They further demonstrated that hTIMs do not directly interact with ZEBOV GP, regardless of whether their mucin domains are present or not. They also solved the IgV domain structures of all the three hTIM family members and revealed individual regional features that were not observed in any of the mouse homologues. These atomic structural observations, together with the solved complex structure of phosphoserine bound to hTIM-4, shed perceptive light on the atomic interactions between PS and hTIMs.

Taken together, the structural and functional data provided by Prof. George Fu Gao's group paved the way for a better understanding of the hTIM-mediated Ebola virus entry.
This research was funded by National Natural Science Foundation of China (NSFC, Grant No. 81590761) and Strategic Priority Research Program of the Chinese Academy of Sciences (XDB08020100).

See the article: Wang H, Qi J X, Liu N N, et al. Crystal structures of human TIM members: Ebolavirus entry-enhancing receptors (in Chinese). Chin Sci Bull, 2015, 60: 3438-3453, doi: 10.1360/N972015-01255

Science China Press

Science China Press

Related Ebola Virus Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

New universal Ebola vaccine may fight all four virus species that infect humans
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.

Researchers show how Ebola virus hijacks host lipids
Robert Stahelin studies some of the world's deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates.

Recognise and control new variants of the deadly Ebola virus more quickly
Joint press release by the DZIF and Charité. The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time.

Investigational drugs reduce risk of death from Ebola virus disease
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).

Researchers learn how Ebola virus disables the body's immune defenses
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can exert such catastrophic effects on the infected person.

Mutant live attenuated Ebola virus immunizes non-human primates
Inoculation with an Ebola virus that has mutations in a protein called VP35 does not cause disease and elicits protection in monkeys, researchers show Sept.

Groundbreaking study could lead to fast, simple test for Ebola virus
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus.

RIT professor develops microfluidic device to better detect Ebola virus
A faculty-researcher at Rochester Institute of technology has developed a prototype micro device with bio-sensors that can detect the deadly Ebola virus.

NEJM applying universal standards of care to Ebola virus disease
LSTM's Senior Clinical Lecturer, Dr. Shevin Jacob, is corresponding author on a perspective piece published in the New England Journal of Medicine calling for universal standards of care to be applied in relation to ebola virus disease.

Read More: Ebola Virus News and Ebola Virus Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to